Design Therapeutics, Inc. DSGN 深 沪
已收盘 04-02 16:00:00 美东时间
11.23
+0.220
+2.00%
华盛通- 最 高11.299
- 今 开10.78
- 成交量 31.43万股
- 最 低 10.709
- 昨 收 11.01
- 总市值 6.93亿
- 52周最高 11.299
- 市盈率 静 --
- 换手率 0.51%
- 52周最低 2.88
- 委 比 -86.79%
- 总股本 6167.23万
- 历史最高 50.50
- 量 比 1.40
- 振 幅 5.36%
- 历史最低 1.94
- 每 手 1
- 风险率 2.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15
Jefferies analyst Faisal Khurshid initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Buy rating and announces Price Target of $15.
03-16 21:16
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monda
03-16 18:00
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Design Therapeutics Q4 EPS $(0.27) Beats $(0.35) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.35) by 23.3 percent. This is a 12.5 percent decrease over losses of $(0.24) per share from
03-10 04:03
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Design Therapeutics reported on the progress of its three clinical programs targeting Friedreich Ataxia (DT-216P2), Fuchs Endothelial Corneal Dystrophy (DT-168), and Myotonic Dystrophy Type-1 (DT-818). The company expects to begin dosing DM1 patients in the first half of 2026. Design also highlighted its financial position with $219.8 million in cash and securities as of year-end, supporting ongoing clinical trials. Net loss for the year was $69....
03-09 20:01
Design Therapeutics to Present at Oppenheimer Annual Healthcare Life Sciences Conference and Leerink Partners Global Healthcare Conference
Design Therapeutics to Present at Oppenheimer Annual Healthcare Life Sciences Conference and Leerink Partners Global Healthcare Conference Design Therapeutics Inc. will present virtually at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 (1:20 p.m. ET) and will a
02-18 21:01
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, Inc. announced that its management will present at two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, and the Leerink Partners Global Healthcare Conference on March 10, 2026. Live webcasts will be available on the company’s website and will be archived for at least 30 days. The company, focused on developing gene-targeted therapies, is advancing several cli...
02-18 13:00
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18
Oppenheimer analyst Trevor Allred initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Outperform rating and announces Price Target of $18.
01-07 20:36
